|Bid||2.5100 x 3000|
|Ask||2.5200 x 800|
|Day's Range||2.4700 - 2.7250|
|52 Week Range||2.4100 - 6.5000|
|Beta (5Y Monthly)||2.66|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 02, 2022 - Mar 07, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.30|
Subscribe to Yahoo Finance Plus to view Fair Value for ABUSLearn more
Investment company First Quadrant L P (Current Portfolio) buys Innoviva Inc, NOW Inc, General Electric Co, CF Industries Holdings Inc, JPMorgan Chase, sells , Brookfield Asset Management Inc, , Roku Inc, Cardiovascular Systems Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, First Quadrant L P.
Multiple AB-729 and AB-836 HBV clinical data readouts anticipated to guide future clinical development and regulatory strategies Complete IND-enabling studies for oral PD-L1 inhibitor, AB-101, for the treatment of HBV Complete IND-enabling studies for next generation oral RNA destabilizer, AB-161, for the treatment of HBVAdvance an nsp5 main protease (Mpro) inhibitor candidate into IND-enabling studies for treatment of SARS-CoV-2 Financial position significantly strengthened; cash runway into Q2
Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.